Targeted & controlled bone healing
MagnetOs has an advanced submicron surface topography that directs bone formation.
What is MagnetOs?
MagnetOs is a bone graft comprising biphasic calcium phosphate [1,2,3] in the form of 1-2mm or 2-4mm porous granules. Using a patented process, a novel submicron surface structure is applied to MagnetOs during manufacturing [4]. After implantation, new bone is deposited directly on the surface of MagnetOs [1,2,3].
MagnetOs resembles human bone
MagnetOs is osteoconductive and has a porous trabecular structure that resembles the interconnected structure of human cancellous bone [1,2,3]. The porosity of MagnetOs is 70% which matches the porosity of human cancellous bone in males and females at defect sites in the body where MagnetOs is indicated, for example, when used over the facet joints in the spine to achieve posterolateral fusion [5].
MagnetOs is equivalent to the “gold standard” bone graft in cleared indications §
Autologous bone graft is the “gold standard” graft material for spinal fusion procedures [6] despite significant disadvantages, including donor-site morbidity [7]. MagnetOs has been rigorously tested against autologous bone graft in a validated, clinically relevant preclinical model [8]. As a bone autograft extender, MagnetOs promoted progressive spine fusion with fusion rates equivalent to the “gold standard” autologous bone graft [9].
MagnetOs Putty is moldable for filling defects in the spine
MagnetOs comes in a putty formulation in which MagnetOs granules are premixed with a polymeric binder that facilitates application to bony defects in the spine. MagnetOs Putty can be shaped by the surgeon to conform to the contours of the defect. After implantation, the polymeric binder in the putty is rapidly resorbed leaving the granules of MagnetOs to guide the three-dimensional regeneration of bone [2].
References:
[1] Instructions for Use (IFU) MAGNETOS Granules (US) - Graft extender in spine
[2] Instructions for Use (IFU) MAGNETOS Putty (US) - Graft extender in spine
[3] Instructions for Use (IFU) MAGNETOS Granules (EU)
[4] Patent pending, US patent application 14/904,676
[5] Wilke et al. J. Anat. (2012) 220, pp233–241
[6] Morris et al. Eur Spine J. 2018 Feb 14. [Epub ahead of print]
[7] Banwart et al. Spine. 1995;20:1055-1060
[8] Boden et al. Spine. 1995;20:412-420
[9] Data on file (RPT 15064)
§ results from testing in animals may not be predictive of human clinical experience
Kuros Biosciences B.V. or other corporate affiliated entities own, use or have applied for the following trademarks or service marks: Magnetos; Kuros Biosciences. Chronos® is a registered trademark of DePuy Synthes, Inc., Vitoss® is a registered trademark of Stryker Corp., Actifuse® is a registered trademark of Baxter International Inc., and AttraX is a trademark of NuVasive, Inc.
